diphenylamine has been researched along with Acute Myelogenous Leukemia in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alexe, G; Armstrong, SA; Blachly, JS; Byrd, JC; Chu, SH; Cremer, A; Ellegast, JM; Frank, ES; Goodale, A; Häupl, B; Mohr, S; Oellerich, T; Piccioni, F; Pikman, Y; Rao, AV; Robichaud, A; Ross, L; Stegmaier, K; Walker, AR | 1 |
| Bruner, JK; Jones, RJ; Levis, MJ; Li, L; Ma, HS; Pratilas, CA; Pratz, KW; Qin, ACR; Rudek, MA; Small, D | 1 |
| Akagi, K; Asthana, S; Bielski, CM; Burgess, MR; Crocker, L; Davis, EM; Evangelista, M; Firestone, AJ; Haley, B; Huang, BJ; Hwang, E; Lacap, JA; Le Beau, MM; Li, Q; Mroue, R; Sampath, D; Shannon, K; Stokoe, D; Taylor, BS; Wandler, AM; Xu, J; Young, A | 1 |
| Andreeff, M; Bergamo, P; Bornmann, W; Chen, W; Konopleva, M; Korchin, B; Mak, DH; McCubrey, J; McQueen, T; Milella, M; Ricciardi, MR; Ruvolo, P; Tafuri, A; Tsao, T; Watts, JC | 1 |
| Abrams, SL; Andreeff, M; Bergamo, P; Chiaretti, S; Ciuffreda, L; Cognetti, F; Del Bufalo, D; Foà, R; Konopleva, M; Marchetti, A; Mascolo, MG; McCubrey, JA; Milella, M; Petrucci, MT; Ricciardi, MR; Scerpa, MC; Steelman, LS; Tafuri, A; Tavolaro, S; Tsao, T | 1 |
5 other study(ies) available for diphenylamine and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diphenylamine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Leukemic; Humans; Indazoles; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase Kinases; Mutagenesis, Site-Directed; Mutation; Open Reading Frames; Primary Cell Culture; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Pyrazines; Syk Kinase; Xenograft Model Antitumor Assays | 2020 |
Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Diphenylamine; Female; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Random Allocation; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Clonal Evolution; Colorectal Neoplasms; Diphenylamine; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Mice; Mutation; Proto-Oncogene Proteins p21(ras); Retroviridae | 2017 |
MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Benzamides; Biphenyl Compounds; Cell Line, Tumor; Diphenylamine; Extracellular Signal-Regulated MAP Kinases; Humans; Leukemia, Myeloid, Acute; Membrane Proteins; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2012 |
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzenesulfonates; Cell Proliferation; Cell Survival; Diphenylamine; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; MAP Kinase Kinase 1; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib; Transcriptome; Tumor Cells, Cultured | 2012 |